Ali Pashazadeh in PRISM (Arthur D. Little)
PRISM, the management journal published by Arthur D. Little since 1988 and distributed to a senior audience across the firm’s offices in some 30 countries, featured Ali Pashazadeh, CEO and Founder of Treehill Partners, as the only external expert quoted in a feature by Helen Albert on speed to market in drug development.
The article’s premise is that being first to market can be worth billions in revenue advantage, making speed a board-level strategic priority rather than a purely operational concern. Pashazadeh’s contribution reframed what speed should actually mean. He described advising a company whose technology was genuinely promising but directed at the wrong patient indication – one the FDA would most likely have blocked. Rather than accelerate a flawed plan, his team changed the development pathway entirely, redirecting the program toward a patient population where the regulatory path was more favourable. The early science, he noted, had been correct; what had to change was how the company anticipated the regulator’s response. It is a concise illustration of Treehill’s clinical development optimization approach: strategic and regulatory relevance, engineered in from the outset, is what actually determines speed.
Read the full article on: https://prism.adlittle.com/fast-pharma-the-cost-of-coming-second-in-clinical-trials/
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.